Table 3 Associations between plasma liver-type fatty acid-binding protein and clinicopathological characteristics in the breast cancer patients
Parameters | L-FABP (ng/ml) | p-value | |
|---|---|---|---|
> 7.6 (n = 98) | ≤ 7.6 (n = 98) | ||
Tumor size (cm) | |||
 ≤ 1 | 25 (25.5) | 37 (37.8) | 0.065 |
 > 1 | 73 (74.5) | 61 (62.2) |  |
Pathologic T stage | |||
 T0+T1 | 39 (39.8) | 53 (54.1) | 0.045 |
 T2+T3+T4 | 59 (60.2) | 45 (45.9) |  |
Lymph node metastasis | |||
 N0+N1 | 84 (85.7) | 92 (93.9) | 0.059 |
 N2+N3 | 14 (14.3) | 6 (6.1) |  |
Histologic grade | |||
 1 | 51 (52.0) | 58 (59.2) | 0.314 |
 ≥ 2 | 47 (48.0) | 40 (40.8) |  |
Clinical stage | |||
 Stage I | 36 (36.7) | 53 (54.1) | 0.015 |
 Stage II | 38 (38.8) | 31 (31.6) | 0.295 |
 Stage III | 24 (24.5) | 14 (14.3) | 0.045 |
Estrogen receptor status | |||
 Positive | 77 (78.6) | 88 (89.8) | 0.031 |
 Negative | 21 (21.4) | 10 (10.2) |  |
Progesterone receptor status | |||
 Positive | 74 (75.5) | 66 (67.4) | 0.206 |
 Negative | 24 (24.5) | 32 (32.7) |  |
HER-2 receptor status | |||
 Positive | 62 (63.3) | 47 (48.0) | 0.029 |
 Negative | 36 (36.7) | 51 (52.0) |  |